CN1268055A - 含有尼维瑞平半水合物的药物悬浮液 - Google Patents
含有尼维瑞平半水合物的药物悬浮液 Download PDFInfo
- Publication number
- CN1268055A CN1268055A CN98808489A CN98808489A CN1268055A CN 1268055 A CN1268055 A CN 1268055A CN 98808489 A CN98808489 A CN 98808489A CN 98808489 A CN98808489 A CN 98808489A CN 1268055 A CN1268055 A CN 1268055A
- Authority
- CN
- China
- Prior art keywords
- nevirapine
- hemihydrate
- milliliters
- usp
- adjusted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明是关于一种水性药物悬浮液,其中主要包含粒径介于约1至150微米的尼维瑞平(nevirapine)半水合物。
Description
本发明是关于一种新颖组合物，它是包含尼维瑞平(nevirapine)半水合物的一种药物悬浮液。
尼维瑞平，或是11-环丙基-5，11-二氢-4-甲基-6H-二吡啶并[3，2-b：2′，3’-e][1，4]二氮杂-6-酮是一种用于治疗由HIV-1(I型人类免疫缺陷)感染的已知制剂，其作用是通过特异性的抑制HIV-1(I型人类免疫缺陷病毒)的逆转录酶。其合成和用途已描述于不同的专利，包括，特别是，美国专利No.5,366,972；欧洲专利申请No.0 429 987，美国专利申请系列No08/515093(代理案号No 09/051-3-C3，已付出版费)和美国专利申请系列号No 08/371622(代理案号No 1/981，已付出版费)。维若敏(Viramune)片剂，是一种包含尼维瑞平的药物片剂，最近刚被美国食品药物检验局准许用于治疗HIV-1(I型人类免疫缺陷病毒)感染。
安琪等人(Angel et al.)[美国电子显微镜协会第50届年会手册，1326-1327页(1992)]曾发表尼维瑞平是以半水合物的稳定态存在及以无水的亚稳态存在。同一篇文献中曾提到企图由该化合物的无水态制成适于儿科使用的尼维瑞平水性悬浮液。该尝试并未成功，因为一旦被制成水性悬浮液后，无水的尼维瑞平会缓慢的转换成半水合物态，产生半水合物结晶，随着时间的过程，结晶变大而对药物的溶解和药物的效用产生负影响。
本发明是尼维瑞平半水合物的水性悬浮液。意外地发现，在水性悬浮液中，半水合物的结晶在时间过程是稳定的。因此，尼维瑞平半水合物的水性悬浮液是药物上可接受的。
可利用包括上述提及的文献中的已知的多种方法中的任一种制备无水尼维瑞平。
该半水合物可简便地由水性液中将无水物料经再结晶而制成。它可通过将自由碱的无水物料的水性悬浮液与强酸反应，如盐酸，则产生酸加成盐。再将该盐与强碱反应，如氢氧化钠，以产生半水合物态的自由碱沉淀。将沉淀以过滤方式由水性液中取出，以水洗后，使之干燥至水含量为约3.1至3.9重量％。过度干燥将使半水合物转换为无水态，所以应避免。术语半水合物是指含有约0.5mole水的尼维瑞平。
为用于药物上可接受的水性悬浮液，半水合物的粒径应在约1至150微米。根据上述所产生的半水合物，若有需要，可经研磨以使颗粒大小落入该范围内。
一种药物上可接受的尼维瑞平半水合物水性悬浮液的制备，是将半水合物以1至50毫克尼维瑞平半水合物对1毫升水的比率加入纯水中，接着搅拌混合。该制剂中可另外含有传统的药物添加剂，如下述，但不仅限于这些，悬浮制剂和/或粘度增稠剂，如，纤维素基的聚合物或合成的聚合物，优选为交联的聚合物，如卡勃姆(carbomers)；湿润剂如，聚环氧乙烷或聚氧乙烯脱水山梨醇脂肪酸酯(多乙氧基醚)；甜味剂或调味剂，如蔗糖；和防腐剂，如对氧苯甲酸酯。
通过非限制性的描述，根据本发明的典型制剂将示于下表。
| 组成 | 用量(克/100毫升) |
| 尼维瑞平半水合物 | 0.1-5.0 |
| 卡勃姆(Carbomer)934P，NF | 0.17-0.22 |
| 多乙氧基醚80，NF | 0.01-0.2 |
| 山梨糖醇溶液，USP | 5-30 |
| 蔗糖，NF | 5-30 |
| 对氧苯甲酸甲酯，NF | 0.15-0.2 |
| 对氧苯甲酸丙酯，NF | 0.02-0.24 |
| 氢氧化钠，N.F.* | 适量以调整至pH5.5-6.0 |
| 纯水，USP | 适量以调整至100.0毫升 |
*制成20％溶液
本发明更以下述非限制性实例以进一步说明。实施例1尼维瑞平半水合物的制备
对含有318公斤的尼维瑞平(无水)的玻璃衬反应器中以低流速加入319公斤的37％盐酸，以维持内部的温度低于35℃。将该混合物在25-35℃下搅拌至所有的物料都溶解。将溶液过滤后，并以160升的纯水稀释。以25％氢氧化钠溶液中和，但需维持其温度低于40℃。使所得的结晶悬浮液冷却至15-20℃达30分钟。将该结晶离心后，以纯水洗，并使其于30-40℃下干燥。利用通常的真空转筒干燥器在真空下干燥该结晶8-24小时，再以空气循环槽式干燥器进行24-72小时，或是在Titus离心干燥器(TZD)中进行1-8小时。使所得的半水合物药品持续干燥至利用湿度计于100℃下测量30分钟，其水含量为介于3.1-3.9％。实施例2尼维瑞平半水合物的制备
将26克尼维瑞平(无水)悬浮于100毫升水中。在冷却下将30毫升浓盐酸加入搅拌中的混合物，以保持温度低于30℃。10-20分钟后，将有色的溶液过滤，并添加溶于50毫升水中的14.4克氢氧化钠以进行中和。将所得的沉淀过滤后并以水洗。将湿的结晶物移入槽内，并于35-45℃中干燥至水含量为介于3.1-3.9％为止。所得的半水合物的熔点是242-245℃，且经分析含有3.1-3.6％的水，或是约0.5mole的水。实施例3制备水性50毫克/毫升的尼维瑞平半水合物的药物悬浮液
| 组成 | 用量(克/100毫升) |
| 尼维瑞平半水合物 | 1.035 |
| 卡勃姆(Carbomer)934P，NF | 0.2100 |
| 多乙氧基醚80，NF | 0.05000 |
| 山梨糖醇溶液，USP | 23.13 |
| 蔗糖，NF | 15.0 |
| 对氧苯甲酸甲酯，NF | 0.1800 |
| 对氧苯甲酸丙酯，NF | 0.02400 |
| 氢氧化钠，N.F.* | 适量以调整至pH5.5-6.0 |
| 纯水，USP | 适量以调整至100.0毫升 |
*制成20％溶液制备方法
将部分纯水加热至约70℃，在连续搅拌混合下加入对氧苯甲酸甲酯和对氧苯甲酸丙酯。当对氧苯甲酸酯完全溶解后，使溶液冷却至35℃以下，再在搅拌下分散加入卡勃姆934P於该经防腐的溶液中。以20％氢氧化纳溶液调节pH值至5.5-5.8。将该胶状物持续搅拌约20分钟，再重测pH值。在搅拌下添加山梨糖醇溶液。再加入蔗糖且继续搅拌30分钟。将多乙氧基醚80溶于一部分纯水中，再将尼维瑞平加入多氧乙基醚80溶液中，并将该混合物均质搅拌至少40分钟。将尼维瑞平/多氧乙基醚80药物浓缩物完全混入卡勃姆胶中。以纯水调节该悬浮液的体积或重量，且搅拌30分钟。
Claims (4)
1.一种制备尼维瑞平(nevirapine)水性悬浮液的方法，该方法包括将粒径介于约1至150微米的尼维瑞平半水合物与水相混合。
2.一种药物组合物，其中主要包括粒径在约1至150微米的尼维瑞平半水合物及水。
3.一种药物组合物，其中主要含有下述在指定相对用量范围内的组成：
组成
用量范围(克/100毫升)
尼维瑞平半水合物
0.1-5.0
卡勃姆(Carbomer)934P，NF
0.17-0.22
多乙氧基醚80，NF
0.01-0.2
山梨糖醇溶液，USP
5-30
蔗糖，NF
5-30
对氧苯甲酸甲酯，NF
0.15-0.2
对氧苯甲酸丙酯，NF
0.02-0.24
氢氧化钠，N.F.*
适量以调整至pH5.5-6.0
纯水，USP
适量以调整至100.0毫升
*制成20％溶液
其中尼维瑞平的粒径介于约1至150微米。
4.根据权利要求3的药物组合物，其中主要包含下述在指定相对用量范围内的组成：
组成
用量范围(克/100毫升)
尼维瑞平半水合物
1.035
卡勃姆(Carbomer)934P，NF
0.1900
多乙氧基醚80，NF
0.05000
山梨糖醇溶液，USP
23.13
蔗糖，NF
15.00
对氧苯甲酸甲酯，NF
0.1800
对氧苯甲酸丙酯，NF
0.02400
氢氧化钠，N.F.*
适量以调整至pH5.5-6.0
纯水，USP
适量以调整至100.0毫升
*制成20％溶液
其中尼维瑞平的粒径介于约1至150微米。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5680397P | 1997-08-25 | 1997-08-25 | |
| US60/056,803 | 1997-08-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1268055A true CN1268055A (zh) | 2000-09-27 |
| CN1197578C CN1197578C (zh) | 2005-04-20 |
Family
ID=22006658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB988084899A Expired - Fee Related CN1197578C (zh) | 1997-08-25 | 1998-08-11 | 含有尼维瑞平半水合物的药物悬浮液 |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US6172059B1 (zh) |
| EP (1) | EP1019058B1 (zh) |
| JP (1) | JP3472261B2 (zh) |
| KR (1) | KR100426516B1 (zh) |
| CN (1) | CN1197578C (zh) |
| AR (2) | AR016869A1 (zh) |
| AT (1) | ATE326971T1 (zh) |
| AU (1) | AU742761B2 (zh) |
| BG (1) | BG64337B1 (zh) |
| BR (1) | BR9811994B1 (zh) |
| CA (1) | CA2301646C (zh) |
| CL (1) | CL2008003111A1 (zh) |
| CO (1) | CO4970742A1 (zh) |
| CY (1) | CY1105228T1 (zh) |
| CZ (1) | CZ290667B6 (zh) |
| DE (1) | DE69834655T2 (zh) |
| DK (1) | DK1019058T3 (zh) |
| EG (1) | EG24075A (zh) |
| ES (1) | ES2265666T3 (zh) |
| HK (1) | HK1027975A1 (zh) |
| HR (1) | HRP980461B1 (zh) |
| HU (1) | HU226063B1 (zh) |
| ID (1) | ID21650A (zh) |
| IL (1) | IL134185A (zh) |
| MY (1) | MY122272A (zh) |
| NO (1) | NO326226B1 (zh) |
| NZ (1) | NZ503414A (zh) |
| PE (1) | PE105799A1 (zh) |
| PL (1) | PL192361B1 (zh) |
| PT (1) | PT1019058E (zh) |
| RS (1) | RS49808B (zh) |
| RU (1) | RU2196584C2 (zh) |
| SA (1) | SA98190680B1 (zh) |
| TR (1) | TR200000490T2 (zh) |
| TW (1) | TW450812B (zh) |
| UA (1) | UA44370C2 (zh) |
| WO (1) | WO1999009990A1 (zh) |
| ZA (1) | ZA987623B (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002092095A1 (en) * | 2001-05-11 | 2002-11-21 | Boehringer Ingelheim International Gmbh | Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine |
| EP1504040A1 (en) * | 2002-04-23 | 2005-02-09 | Boehringer Ingelheim Pharmaceuticals Inc. | Method for reduction of residual organic solvent in carbomer |
| KR20080053317A (ko) * | 2005-08-31 | 2008-06-12 | 씨아이피엘에이 엘티디. | 라미부딘, 스타부딘 및 네비라핀을 포함하는 약학적 조합물 |
| US20110082161A1 (en) * | 2008-06-30 | 2011-04-07 | Lieven Elvire Colette Baert | Powders for reconstitution |
| BR112012011095A2 (pt) * | 2009-11-10 | 2015-10-06 | Univ Northwest | método para aumentar a solubilidade de uma composição inibidora de transcriptase |
| DE112010004862T5 (de) * | 2009-12-17 | 2012-12-06 | North West University | Polymorphe Form von Nevirapin und deren Herstellung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5366972A (en) | 1989-04-20 | 1994-11-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection |
| CA2030056C (en) * | 1989-11-17 | 1995-10-17 | Karl D. Hargrave | 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection |
| US5571912A (en) * | 1990-10-19 | 1996-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines |
| DE4403311C1 (de) * | 1994-02-03 | 1995-04-20 | Boehringer Ingelheim Kg | Verfahren zur Herstellung von Nevirapine (11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4-diazepin]-6-on) |
-
1998
- 1998-08-11 UA UA2000031668A patent/UA44370C2/uk unknown
- 1998-08-11 AT AT98939312T patent/ATE326971T1/de active
- 1998-08-11 AU AU87771/98A patent/AU742761B2/en not_active Ceased
- 1998-08-11 WO PCT/US1998/016581 patent/WO1999009990A1/en active IP Right Grant
- 1998-08-11 US US09/131,829 patent/US6172059B1/en not_active Expired - Lifetime
- 1998-08-11 BR BRPI9811994-0B1A patent/BR9811994B1/pt not_active IP Right Cessation
- 1998-08-11 KR KR10-2000-7001889A patent/KR100426516B1/ko not_active IP Right Cessation
- 1998-08-11 CA CA002301646A patent/CA2301646C/en not_active Expired - Fee Related
- 1998-08-11 TR TR2000/00490T patent/TR200000490T2/xx unknown
- 1998-08-11 RU RU2000107825/14A patent/RU2196584C2/ru not_active IP Right Cessation
- 1998-08-11 DK DK98939312T patent/DK1019058T3/da active
- 1998-08-11 NZ NZ503414A patent/NZ503414A/xx not_active IP Right Cessation
- 1998-08-11 HU HU0003093A patent/HU226063B1/hu not_active IP Right Cessation
- 1998-08-11 PL PL338828A patent/PL192361B1/pl unknown
- 1998-08-11 EP EP98939312A patent/EP1019058B1/en not_active Expired - Lifetime
- 1998-08-11 JP JP2000507380A patent/JP3472261B2/ja not_active Expired - Fee Related
- 1998-08-11 CN CNB988084899A patent/CN1197578C/zh not_active Expired - Fee Related
- 1998-08-11 ES ES98939312T patent/ES2265666T3/es not_active Expired - Lifetime
- 1998-08-11 DE DE69834655T patent/DE69834655T2/de not_active Expired - Lifetime
- 1998-08-11 PT PT98939312T patent/PT1019058E/pt unknown
- 1998-08-11 CZ CZ2000694A patent/CZ290667B6/cs not_active IP Right Cessation
- 1998-08-11 IL IL13418598A patent/IL134185A/xx not_active IP Right Cessation
- 1998-08-11 RS YUP-98/00A patent/RS49808B/sr unknown
- 1998-08-11 PE PE1998000718A patent/PE105799A1/es not_active Application Discontinuation
- 1998-08-21 MY MYPI98003819A patent/MY122272A/en unknown
- 1998-08-23 EG EG98398A patent/EG24075A/xx active
- 1998-08-24 HR HR980461A patent/HRP980461B1/xx not_active IP Right Cessation
- 1998-08-24 ID IDP981156A patent/ID21650A/id unknown
- 1998-08-24 TW TW087113878A patent/TW450812B/zh not_active IP Right Cessation
- 1998-08-24 CO CO98048247A patent/CO4970742A1/es unknown
- 1998-08-24 ZA ZA9807623A patent/ZA987623B/xx unknown
- 1998-08-25 AR ARP980104200A patent/AR016869A1/es not_active Ceased/Invalidation/Refusal/Rejection/Nullification
- 1998-11-01 SA SA98190680A patent/SA98190680B1/ar unknown
-
2000
- 2000-02-07 BG BG104133A patent/BG64337B1/bg active Active
- 2000-02-24 NO NO20000906A patent/NO326226B1/no not_active IP Right Cessation
- 2000-03-02 US US09/517,564 patent/US6255481B1/en not_active Expired - Lifetime
- 2000-11-20 HK HK00107393A patent/HK1027975A1/xx not_active IP Right Cessation
-
2006
- 2006-08-11 CY CY20061101147T patent/CY1105228T1/el unknown
-
2008
- 2008-10-21 CL CL2008003111A patent/CL2008003111A1/es unknown
-
2011
- 2011-10-14 AR ARP110103815A patent/AR083451A2/es active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3980766A (en) | Orally administered drug composition for therapy in the treatment of narcotic drug addiction | |
| JPS62298533A (ja) | 高コレステロ−ル血症治療薬およびその製造方法 | |
| JPS62126122A (ja) | 表面コ−テイングされたイブプロフエン顆粒の製法 | |
| US3282789A (en) | Stable liquid colloidal tannate compositions | |
| CN1197578C (zh) | 含有尼维瑞平半水合物的药物悬浮液 | |
| US6589955B2 (en) | Pediatric formulation of gatifloxacin | |
| AU2002345534A1 (en) | Pediatric formulation of gatifloxacin | |
| CN1128999A (zh) | 杂环化合物 | |
| CN102180785A (zh) | 赖氨洛芬的合成及其用途 | |
| CA1151153A (en) | Penicillin salt | |
| CA2617000C (en) | Methods for preparing nevirapine hemihydrate and an aqueous suspension thereof | |
| JPH02225422A (ja) | 薬剤組成物 | |
| MXPA00001392A (en) | Pharmaceutical suspension comprising nevirapine hemihydrate | |
| Jain et al. | Formulation and development of taste masked ambroxol hydrochloride suspension using ion exchange resins | |
| IE44733B1 (en) | Theophylline compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050420 Termination date: 20150811 |
|
| EXPY | Termination of patent right or utility model |